After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility.
Stocks Info
XENE belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. The current market capitalization of Xenon Pharmaceuticals Inc is $2.56B. A total of 1.28 million shares were traded on the day, compared to an average of 1.30M shares.
In the most recent transaction, GANNON STEVEN sold 3 shares of XENE for 30.48 per share on Jun 05 ’25. After the transaction, the Director now owns 7,141 company shares. In a previous transaction on Jan 24 ’25, MORTIMER IAN sold 22,468 shares at 40.20 per share. XENE shares that PRESIDENT & CEO owns now total 31,302.
Among the insiders who sold shares, MORTIMER IAN disposed of 16,315 shares on Jan 27 ’25 at a per-share price of $40.50. This resulted in the PRESIDENT & CEO holding 31,302 shares of XENE after the transaction. In another insider transaction, MORTIMER IAN sold 16,217 shares at $40.08 per share on Jan 23 ’25. Company shares held by the PRESIDENT & CEO now total 31,302.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, XENE has a high of $46.00 and a low of $26.74.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. XENE’s latest balance sheet shows that the firm has $551.77M in Cash & Short Term Investments as of fiscal 2021. There were $8.26M in debt and $14.32M in liabilities at the time. Its Book Value Per Share was $9.19, while its Total Shareholder’s Equity was $550.03M.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for XENE is Buy with a score of 4.89.
